Log in

NASDAQ:KMDAKamada Stock Price, Forecast & News

$8.83
+0.02 (+0.23 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$8.60
Now: $8.83
$9.14
50-Day Range
$6.71
MA: $8.12
$9.45
52-Week Range
$4.40
Now: $8.83
$9.91
Volume340,249 shs
Average Volume224,749 shs
Market Capitalization$393.11 million
P/E Ratio16.35
Dividend YieldN/A
Beta1.2
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus, as well as human transferrin that is used as a cultural medium for diagnostic assays and cell cultures. In addition, Kamada Ltd. provides Heparin sodium injection to treat thrombo-embolic disorders; Albumin and Albumin 4% for maintenance of blood plasma; and coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine. Its products in pipeline are G1-AAT (IV) for graft versus host disease and L1-AAT (1V) for lung transparent, which are in Phase II stage; and D1-AAT (IV) for type-1 diabetes, Inhaled AAT for AAT deficiency, and AAT (liquid) for lung preservation and recombinant AAT, which are in early stage development. Further, the company distributes respiratory products, including Bramitob to manage chronic pulmonary infection and FOSTER for the treatment of asthma; and immunoglobulins comprising IVIG 5% for the treatment of various immunodeficiency-related conditions; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for prevention of hepatitis B virus; and Megalotect, a CMV immunoglobulin. It markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceutical Company Limited; PARI GmbH; and Kedrion S.p.A. Kamada Ltd. was founded in 1990 and is headquartered in Rehovot, Israel.
Read More
Kamada logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.07 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KMDA
CUSIPN/A
Phone972-8940-6472

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$127.19 million
Cash Flow$0.60 per share
Book Value$3.04 per share

Profitability

Net Income$22.25 million

Miscellaneous

Employees408
Market Cap$393.11 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive KMDA News and Ratings via Email

Sign-up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter.

Kamada (NASDAQ:KMDA) Frequently Asked Questions

How has Kamada's stock been impacted by COVID-19 (Coronavirus)?

Kamada's stock was trading at $5.15 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KMDA stock has increased by 71.5% and is now trading at $8.83. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Kamada?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kamada.

When is Kamada's next earnings date?

Kamada is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Kamada.

How were Kamada's earnings last quarter?

Kamada Ltd. (NASDAQ:KMDA) released its earnings results on Wednesday, February, 12th. The biotechnology company reported $0.13 EPS for the quarter, meeting the Thomson Reuters' consensus estimate of $0.13. The biotechnology company had revenue of $32.07 million for the quarter, compared to the consensus estimate of $31.63 million. Kamada had a net margin of 16.87% and a return on equity of 16.24%. View Kamada's earnings history.

What guidance has Kamada issued on next quarter's earnings?

Kamada issued an update on its FY 2020 Pre-Market earnings guidance on Monday, May, 18th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $132-137 million, compared to the consensus revenue estimate of $134.76 million.

What price target have analysts set for KMDA?

1 equities research analysts have issued 1 year price objectives for Kamada's stock. Their forecasts range from $11.00 to $11.00. On average, they expect Kamada's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 24.6% from the stock's current price. View analysts' price targets for Kamada.

What are Wall Street analysts saying about Kamada stock?

Here are some recent quotes from research analysts about Kamada stock:
  • 1. According to Zacks Investment Research, "Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. " (6/23/2020)
  • 2. HC Wainwright analysts commented, "Our price target of $11/share is based on an equally weighted composite of: (a) $14.26/share, as a 35x multiple of taxed and diluted FY23 GAAP EPS of $0.84 discounted back to and (b) an NPV of $8.1/share (discount rate 12%, growth rate 2%). Risks to our investment thesis and target price include: (1) failure of AAT (IV and IH) to achieve peak commercial revenue estimates in our model (due to market size, penetration rates, and/ or pricing); (2) failure of IH-AAT in clinical studies; (3) failure of IH-AAT to secure regulatory approval; and (4) other potential pipeline failures." (8/7/2019)

Has Kamada been receiving favorable news coverage?

Headlines about KMDA stock have trended negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kamada earned a daily sentiment score of -2.2 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the near term. View the latest news about Kamada.

Are investors shorting Kamada?

Kamada saw a increase in short interest in the month of June. As of June 15th, there was short interest totaling 89,500 shares, an increase of 69.2% from the May 31st total of 52,900 shares. Based on an average daily volume of 107,100 shares, the short-interest ratio is currently 0.8 days. Approximately 0.4% of the shares of the stock are short sold. View Kamada's Current Options Chain.

Who are some of Kamada's key competitors?

What other stocks do shareholders of Kamada own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Zoetis (ZTS) and Micron Technology (MU).

Who are Kamada's key executives?

Kamada's management team includes the following people:
  • Mr. Amir London, Chief Exec. Officer (Age 50)
  • Mr. Chaime Orlev, Chief Financial Officer (Age 49)
  • Mr. Eran Nir, VP of Operations & Plant Mang. (Age 46)
  • Mr. David Tsur, Co-Founder & Active Deputy Chairman (Age 68)
  • Dr. Naveh Tov M.D., Ph.D., VP of Clinical Devel. & Medical Director for Pulmonary Diseases (Age 55)

What is Kamada's stock symbol?

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

How do I buy shares of Kamada?

Shares of KMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kamada's stock price today?

One share of KMDA stock can currently be purchased for approximately $8.83.

How big of a company is Kamada?

Kamada has a market capitalization of $393.11 million and generates $127.19 million in revenue each year. The biotechnology company earns $22.25 million in net income (profit) each year or $0.55 on an earnings per share basis. Kamada employs 408 workers across the globe.

What is Kamada's official website?

The official website for Kamada is www.kamada.com.

How can I contact Kamada?

Kamada's mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The biotechnology company can be reached via phone at 972-8940-6472 or via email at [email protected]

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.